Neutralizing antibodies to interferon-alpha and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-alpha-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Date publication

décembre 2010

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Halfon P, Perusat S, Bourliere M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chene G, Couzigou P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20981789

Résumé

A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)-interferon (IFN)-alpha-2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN-alpha-2a. The aim of this study was to assess neutralizing antibodies to IFN-alpha-2a and IFN levels in non-responder patients who were re-treated by PEG IFN-alpha-2a and RIBA for 12 weeks. Non-responders to a first-line treatment of PEG IFN-alpha-2a + RIBA were included for treatment with PEG IFN-alpha-2a (180 microg/week) + RIBA (1,000 mg/day if

Référence

J Med Virol. 2010 Dec;82(12):2027-31.